Scottish healthtech firm Emblation has completed 100,000 treatments in the UK and Ireland with its microwave device for treating skin conditions.

The milestone, achieved by Emblation’s Swift device, has helped clinics across the country bring in more than £11 million in income. The device is now being operated in over 400 clinics across Britain and Northern Ireland with 1,000 practitioners now trained in its use.

Gary Beale, CEO of Emblation said: “When we launched our Swift device into UK clinics from September 2016, we promised to bring benefits to the entire podiatry community where there had been little investment or innovation. We believe we have delivered on that promise.

“The UK has been the pioneer for this treatment, with clinicians grabbing the chance to be the first in the world to use the Swift device. We want to thank each and every clinician who has invested in Swift and helped us reach this amazing landmark. It really is thanks to our loyal and supportive customers that we are now in such an excellent position.”

Emblation also recently secured an eight-figure investment from London-based specialist healthcare investors, Apposite Capital, to support the firm’s growth across Europe and to fund research for further clinical treatments.

The microwave technology Emblation employs offers effective treatments to patients with persistent verrucae, common warts on the feet.

Recommended

• Movers & Shakers | May 2022
• Openreach Scotland appoints first female service delivery director
• Intel announces pending Codeplay Software acquisition

Mr Beale added: “We know that once podiatrists, dermatologists, and other clinicians start using Swift it will rapidly become an invaluable and profitable part of their business.

“Many clinics which have installed a Swift device had never treated verrucae previously as they felt there were no suitable methods. Now they have a thriving verrucae treatment business thanks to Swift.”

Emblation is the first in the country to use this kind of microwave treatment on verrucae and warts. The firm is also growing its research and development capability to treat other skin conditions, including pre-cancerous skin lesions where initial studies have shown positive outcomes.

Based in Central Scotland, the health tech firm has plans for an imminent move into a purpose-built new HQ in Stirling as a result of its continued expansion.

Get the latest news from DIGIT direct to your inbox

Our newsletter covers the latest technology and IT news from Scotland and beyond, as well as in-depth features and exclusive interviews with leading figures and rising stars.

To subscribe, click here.